Bacterial Cocktail to Treat Clostridium difficile Infection: Primum Non Nocere

Million, Matthieu; Lagier, Jean-Christophe; Chaudet, Hervé; Raoult, Didier

doi:10.1093/cid/ciy459

Cited by 2 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, pwMS were dramatically depleted of typically health-associated SCFA-producing bacteria belonging to the Lachnospiraceae family, i.e., Roseburia, Coprococcus, and Blautia. This is a feature common to many disorders, probably resulting from disruptions in the redox state of the intestine [35,36]. In the context of MS, a decreased production of SCFAs, and especially butyrate, could be closely associated with disease-related inflammation, given the crucial involvement of this microbial metabolite in driving Treg differentiation [37,38] and in maintaining the integrity of the intestinal epithelial barrier [39][40][41].…”

Section: Discussionmentioning

confidence: 99%

Influence of a High-Impact Multidimensional Rehabilitation Program on the Gut Microbiota of Patients with Multiple Sclerosis

Barone

Mendozzi

D’Amico

et al. 2021

IJMS

View full text Add to dashboard Cite

Multiple sclerosis (MS) is a neurodegenerative inflammatory condition mediated by autoreactive immune processes. Due to its potential to influence host immunity and gut-brain communication, the gut microbiota has been suggested to be involved in the onset and progression of MS. To date, there is no definitive cure for MS, and rehabilitation programs are of the utmost importance, especially in the later stages. However, only a few people generally participate due to poor support, knowledge, and motivation, and no information is available on gut microbiota changes. Herein we evaluated the potential of a brief high-impact multidimensional rehabilitation program (B-HIPE) in a leisure environment to affect the gut microbiota, mitigate MS symptoms and improve quality of life. B-HIPE resulted in modulation of the MS-typical dysbiosis, with reduced levels of pathobionts and the replenishment of beneficial short-chain fatty acid producers. This partial recovery of a eubiotic profile could help counteract the inflammatory tone typically observed in MS, as supported by reduced circulating lipopolysaccharide levels and decreased populations of pro-inflammatory lymphocytes. Improved physical performance and fatigue relief were also found. Our findings pave the way for integrating clinical practice with holistic approaches to mitigate MS symptoms and improve patients’ quality of life.

show abstract

Section: Discussionmentioning

confidence: 99%

Influence of a High-Impact Multidimensional Rehabilitation Program on the Gut Microbiota of Patients with Multiple Sclerosis

Barone

Mendozzi

D’Amico

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…However, results from many randomized control trials and from the WHO SOLIDARITY trial, conducted in hospitalized patients with COVID-19 in several countries, showed that these antiviral drugs (remdesivir, lopinavir-ritonavir and hydroxychloroquine), have little or no effect on overall mortality, on the application of mechanical ventilation, and on the length of the hospital stay [13,14]. They may even cause adverse side effects particularly for remdesivir and lopinavir-ritonavir including serious gastrointestinal adverse events and also hypoalbuminaemia, hypokalaemia, anaemia, thrombocytopenia, and increased total bilirubin [15,16].…”

Section: Introductionmentioning

confidence: 99%

Study of epidemiological, clinical and evolutionary characteristics of a population of patients hospitalized for COVID-19 in Morocco

et al. 2021

View full text Add to dashboard Cite

The outbreak of COVID-19 still represents a real risk for the increased death rate for the whole of human kind. In this context, the present research work aims at describing evolutionary data in a population of hospitalized COVID-19 positive patients based on selected epidemiological, clinical and paraclinical data at admission. In this cross-sectional study, we examined the data obtained from 108 patients hospitalized with COVID-19 in the VINCI clinic, Casablanca (Morocco) between August and September 2020. General characteristic, clinical, radiological and biological data as well as therapeutic management were assessed. The patients’ median age was 45-50 years old. Among our studied patients, 4.6% were transferred to the intensive care unit (ICU), 16.7% were cured after more than 15 days, while 78.7% were cured within 15 days. Those transferred to the ICU unit were either smokers, obese, or over 65 years of age. The majority of patients with normal radiological and cardiac parameters were cured within<15 days, while biological disorders were observed in approximately all cases that were transferred to ICU. Regarding therapeutic treatment, 98.1% of the subjects were treated with hydroxychloroquine + azithromycin in combination with vitamin C and zinc supplementation. The study shows that the minimal healing time is well conditioned by the general and clinical characteristics of patients. Furthermore, the administration of hydroxychloroquine + azithromycin showed a beneficial effect with no associated adverse effects in the study cases.

show abstract

Bacterial Cocktail to Treat Clostridium difficile Infection: Primum Non Nocere

Cited by 2 publications

References 7 publications

Influence of a High-Impact Multidimensional Rehabilitation Program on the Gut Microbiota of Patients with Multiple Sclerosis

Influence of a High-Impact Multidimensional Rehabilitation Program on the Gut Microbiota of Patients with Multiple Sclerosis

Study of epidemiological, clinical and evolutionary characteristics of a population of patients hospitalized for COVID-19 in Morocco

Contact Info

Product

Resources

About